C. Lepage

发表

Continuing Rapid Increase in Esophageal Adenocarcinoma in England and Wales

M. Coleman, B. Rachet, C. Lepage, 2008, The American Journal of Gastroenterology.

Are the recommendations of the French consensus conference on the management of colon cancer followed up?

C. Lepage, J. Faivre, V. Dancourt, 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial.

P. Laurent-Puig, C. Lepage, S. Martin-Lannerée, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Refractory Bleeding From Gastroduodenal Ulcers: Arterial Embolization in High-operative-risk Patients

J. Cercueil, R. Loffroy, C. Lepage, 2008, Journal of clinical gastroenterology.

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors

P. Laurent-Puig, E. Becht, C. Lepage, 2018, Journal of the National Cancer Institute.

Operative mortality after gastric cancer resection and long‐term survival differences across Europe

D. Forman, C. Lepage, J. Faivre, 2010, The British journal of surgery.

Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)

C. Lepage, R. Guimbaud, C. Quantin, 2015, Health and Quality of Life Outcomes.

Combined SPIO–gadolinium magnetic resonance imaging in cirrhotic patients: negative predictive value and role in screening for hepatocellular carcinoma

J. Cercueil, R. Loffroy, C. Lepage, 2008, Abdominal Imaging.

PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer

P. Laurent-Puig, C. Lepage, V. Jooste, 2015, Cancer medicine.

Management of rectal cancer in France in a well-defined population

V. Bouvier, C. Lepage, V. Jooste, 2014, European journal of gastroenterology & hepatology.

Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.

J. Cercueil, R. Loffroy, C. Lepage, 2018, Journal of hepatology.

Trends in incidence of digestive cancers in France

G. Launoy, C. Lepage, J. Faivre, 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial

A. Amiot, I. Sobhani, M. Boubaya, 2020, Trials.

Trends in incidence and management of cancer of the ampulla of Vater.

C. Lepage, J. Faivre, A. Bouvier, 2014, World journal of gastroenterology.

Long-term Net Survival in Patients With Colorectal Cancer in France: An Informative Contribution of Recent Methodology

C. Lepage, J. Faivre, A. Bouvier, 2013, Diseases of the colon and rectum.

Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study

C. Lepage, J. Faivre, O. Dejardin, 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial

J. Weitz, P. Laurent-Puig, F. Cianchi, 2019, Annals of Surgical Oncology.

Toxicity of Oxaliplatin Plus Fluorouracil/Leucovorin Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer: A Population-Based Study

C. Lepage, J. Faivre, A. Bouvier, 2014, Annals of Surgical Oncology.

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

C. Lepage, O. Bouché, C. Pétorin, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial

F. Brunetti, A. Lièvre, C. Lepage, 2021, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer.

C. Cheze-le Rest, P. Laurent-Puig, H. Sokol, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.

A. Lièvre, P. Laurent-Puig, C. Lepage, 2020 .

Survival from rectal and anal cancers in England and Wales, 1986-2001.

M. Coleman, B. Rachet, C. Lepage, 2006, European journal of cancer.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

C. Borel, C. Lepage, V. Boige, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.

C. Lepage, F. Ghiringhelli, J. Raoul, 2018, European journal of cancer.

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

T. de Baère, M. Ducreux, C. Lepage, 2022, Digestive and Liver Disease.

Incidence and Management of Primary Malignant Small Bowel Cancers: A Well-defined French Population Study

C. Lepage, J. Faivre, V. Dancourt, 2006, The American Journal of Gastroenterology.

Faecal immunochemical tests: a valuable tool for colorectal cancer screening.

C. Lepage, S. Hamza, 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

K. Haustermans, F. Lordick, M. Ducreux, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prospective comparison of whole-body MRI with diffusion-weighted and conventional imaging for the follow-up of neuroendocrine tumors

A. Tabarin, C. Lepage, T. Walter, 2019, Endocrine.

Epidemiology of malignant digestive neuroendocrine tumours

C. Lepage, J. Faivre, A. Bouvier, 2013 .

Incidence and management of malignant digestive endocrine tumours in a well defined French population

C. Lepage, J. Faivre, A. Bouvier, 2004, Gut.

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

C. Lepage, J. Taieb, R. Coriat, 2020, European journal of cancer.

Prevalence of patients with colorectal cancer requiring follow-up or active treatment.

C. Lepage, V. Jooste, J. Faivre, 2009, European journal of cancer.

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904).

C. Lepage, D. Cowen, X. Mirabel, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.

E. Baudin, C. Lepage, J. Scoazec, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.

T. de Baère, C. Lepage, G. Deplanque, 2020, Clinics and research in hepatology and gastroenterology.

A simplified table using validated diagnostic criteria is effective to improve characterization of colorectal polyps: the CONECCT teaching program

T. Ponchon, J. Saurin, A. Becq, 2019, Endoscopy International Open.

Trends in the management and survival of digestive tract cancers among patients aged over 80 years

G. Launoy, C. Lepage, J. Faivre, 2005, Alimentary pharmacology & therapeutics.

Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma

C. Lepage, B. Guiu, S. Aho, 2015, Journal of clinical pharmacy and therapeutics.

Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

B. Chauffert, C. Lepage, A. Denys, 2014, Alimentary pharmacology & therapeutics.

Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study

C. Lepage, V. Jooste, J. Faivre, 2015, Diseases of the colon and rectum.

Incidence and survival in late liver metastases of colorectal cancer

G. Launoy, C. Lepage, V. Jooste, 2015, Journal of gastroenterology and hepatology.

Trends in Frequency and Management of Obstructing Colorectal Cancers in a Well-Defined Population

C. Lepage, J. Faivre, A. Bouvier, 2007, Diseases of the colon and rectum.

Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study

E. Vicaut, E. Baudin, C. Lepage, 2022, Advances in Therapy.

French patient-reported experience of diagnosis, management and burden of neuroendocrine tumors

E. Baudin, C. Lepage, C. Lombard-Bohas, 2020 .

Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial

C. Lepage, N. Kerckhove, D. Pezet, 2022, BMC cancer.

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma

C. Lepage, J. Taieb, J. Bachet, 2022, The oncologist.

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

C. Lepage, V. Jooste, O. Bouché, 2022, European journal of cancer.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Efficacy of treatments for VIPoma: A GTE multicentric series.

C. Lepage, B. Goichot, V. Rebours, 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59

C. Lepage, D. Botsen, O. Bouché, 2022, Biomedicines.

Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.

N. Loménie, A. Lièvre, P. Laurent-Puig, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Loss of SMARCB1 expression in colon carcinoma.

O. Delattre, C. Lepage, J. Mosnier, 2020, Cancer biomarkers : section A of Disease markers.

Transcatheter arterial embolization of splenic artery aneurysms and pseudoaneurysms: short- and long-term results.

J. Cercueil, R. Loffroy, C. Lepage, 2008, Annals of vascular surgery.

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.

A. Lièvre, C. Lepage, C. Lombard-Bohas, 2022, European journal of cancer.

1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

A. Lièvre, C. Lepage, J. Scoazec, 2020 .

Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)

A. Lièvre, M. Ducreux, C. Lepage, 2020, Digestive and Liver Disease.

ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)

P. Laurent-Puig, F. Penault-Llorca, J. Tabernero, 2016 .

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

A. Lièvre, M. Ducreux, C. Lepage, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients

D. Arsène, C. Lepage, G. Deplanque, 2015, PloS one.

Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice

C. Lepage, V. Jooste, V. Quipourt, 2022, Cancers.

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.

P. Laurent-Puig, C. Lepage, J. Emile, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.

M. Loriot, P. Laurent-Puig, C. Lepage, 2013 .

Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study.

B. Chauffert, C. Lepage, P. Maingon, 2014, European journal of cancer.

Early Gastric Cancer: Trends in Incidence, Management, and Survival in a Well-Defined French Population

C. Lepage, V. Jooste, J. Faivre, 2016, Annals of Surgical Oncology.

Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.

D. Aust, R. Salazar, P. Laurent-Puig, 2017 .

Erratum to: Trends in gastric cancer incidence: a period and birth cohort analysis in a well-defined French population

C. Lepage, V. Jooste, J. Faivre, 2016, Gastric Cancer.

Adjuvant chemotherapy for biliary tract cancer

C. Lepage, J. Phelip, X. Coulaud, 2012 .

Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients

S. Msika, A. Lièvre, J. Jougon, 2021, Supportive Care in Cancer.

Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.

C. Lepage, N. Isambert, J. Jouve, 2019, The journal of allergy and clinical immunology. In practice.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

E. Baudin, C. Lepage, P. Rougier, 2017, European journal of cancer.

Colorectal cancer in inflammatory bowel diseases: A population‐based study (1976–2008)

C. Lepage, V. Jooste, J. Faivre, 2012, Inflammatory bowel diseases.

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.

A. Lièvre, C. Lepage, J. Scoazec, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Epidemiology of biliary duct cancers

C. Lepage, J. Phelip, S. Hamza, 2012 .

Hepato-gastroenterologists and oncologists are complementary in the management of digestive cancers.

C. Lepage, P. Rougier, P. Michel, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Incidence, Patterns of Failure, and Prognosis of Perforated Colorectal Cancers in a Well-Defined Population

C. Lepage, J. Faivre, A. Bouvier, 2009, Diseases of the colon and rectum.

Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8.

D. Aust, R. Salazar, P. Laurent-Puig, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[Epidemiology and screening of colon cancer].

C. Lepage, J. Faivre, S. Hamza, 2010, La Revue du praticien.

Epidemiologic characteristics of endocrine tumors of the digestive tract

C. Lepage, A. Bouvier, V. Cottet, 2009 .

Study of Small Intestinal Bacterial Overgrowth in a Cohort of Patients with Abdominal Symptoms Who Underwent Bariatric Surgery

C. Lepage, T. Mouillot, M. Brindisi, 2020, Obesity Surgery.

Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.

P. Laurent-Puig, F. Puglisi, C. Lepage, 2020, Clinics and research in hepatology and gastroenterology.

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort

C. Lepage, D. Spaeth, O. Bouché, 2022, Cancer medicine.

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma

R. Schiappa, C. Lepage, L. Faivre, 2017, Hereditary Cancer in Clinical Practice.

Very high-risk individuals for colorectal cancer: Local oncologic networks are critically needed!

C. Lepage, J. Faivre, S. Manfredi, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer

P. Laurent-Puig, C. Lepage, S. Coutant, 2022, Frontiers in Oncology.

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.

C. Tournigand, M. Loh, P. Senet, 2014, Gastroenterology.

Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies CDH17 and LRP2 as Risk Recurrence Factors in Stage II Colon Cancer

C. Lepage, V. Jooste, M. Callanan, 2022, Cancers.

European disparities in malignant digestive endocrine tumours survival

G. Gatta, C. Lepage, J. Faivre, 2010, International journal of cancer.

Survival from malignant digestive endocrine tumors in England and Wales: a population-based study.

M. Coleman, B. Rachet, C. Lepage, 2007, Gastroenterology.

Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy

J. Cercueil, C. Lepage, L. Duvillard, 2012, European Radiology.

Digestive and Liver Disease

F. Bazzoli, A. Gasbarrini, M. Rugge, 2011 .

Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5.

C. Lepage, J. Faivre, A. Trama, 2015, European journal of cancer.

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).

F. Brunetti, A. Lièvre, C. Lepage, 2020, Annals of surgery.

O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial

L. Collette, P. Laurent-Puig, J. Tabernero, 2012 .

Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population

C. Lepage, J. Faivre, V. Dancourt, 2006, The British journal of surgery.

Copy number variations in DCC/18q and ERBB2/17q are associated with disease‐free survival in microsatellite stable colon cancer

Pierre Michel, Côme Lepage, Ludivine Beaussire, 2017, International journal of cancer.

Why do results conflict regarding the prognostic value of the methylation status in colon cancers? the role of the preservation method

C. Lepage, J. Faivre, F. Piard, 2012, BMC Cancer.

Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

E. Baudin, C. Lepage, C. Lombard-Bohas, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Diverticules gastriques de diagnostic difficile

C. Lepage, J. Quenot, J. Doise, 2004 .

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

L. Collette, R. Salazar, P. Laurent-Puig, 2014, The Lancet. Oncology.

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

D. Aust, R. Salazar, P. Laurent-Puig, 2021, Clinical Cancer Research.

Title: Intra-tumor CMS heterogeneity impacts patient prognosis in localized colon cancer Short title: Intra-tumoral heterogeneity in colon cancer

D. Aust, R. Salazar, P. Laurent-Puig, 2021 .

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study

C. Lepage, J. Emile, F. Ghiringhelli, 2019, Gut.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials

T. Hickish, R. Salazar, J. Tabernero, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).

C. Lepage, R. Guimbaud, V. Boige, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2017, JAMA oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours.

C. Lepage, J. Faivre, A. Bouvier, 2013, European journal of endocrinology.

Repeat Element Activation-Driven Inflammation: Role of NFκB and Implications in Normal Development and Cancer?

C. Lepage, M. Callanan, C. Fournier, 2022, Biomedicines.

Implementation and use of whole exome sequencing for metastatic solid cancer

C. Lepage, R. Boidot, C. Borg, 2020, EBioMedicine.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy

P. Laurent-Puig, J. Tabernero, C. Lepage, 2018, Clinical Cancer Research.

Epidemiology and risk factors for oesophageal adenocarcinoma.

C. Lepage, J. Faivre, J. Jouve, 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Epidemiology and Management of Liver Metastases From Colorectal Cancer

C. Lepage, J. Faivre, A. Bouvier, 2006, Annals of surgery.

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

C. Coutant, N. Sevenet, C. Lepage, 2016, Oncotarget.

The area between ROC curves, a non‐parametric method to evaluate a biomarker for patient treatment selection

Fabien Subtil, Muriel Rabilloud, Pierre Laurent-Puig, 2020, Biometrical journal. Biometrische Zeitschrift.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

P. Laurent-Puig, J. Tabernero, C. Lepage, 2016, JAMA oncology.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

C. Reinhold, C. Borel, C. Lepage, 2019, Gut.

Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene

C. Coutant, C. Lepage, T. Frebourg, 2013, European Journal of Human Genetics.

Epidemiology and prognosis of synchronous colorectal cancers

C. Lepage, V. Jooste, J. Faivre, 2008, British Journal of Surgery.

The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up.

C. Lepage, V. Jooste, J. Faivre, 2008, European journal of cancer.

LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

I. Sobhani, A. Lièvre, C. Lepage, 2022, Annals of Oncology.

LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

N. Girard, C. Lepage, J. Mazières, 2021, Annals of Oncology.

Survival trends for small intestinal cancer in England and Wales, 1971–1990: national population-based study

M. Coleman, B. Rachet, C. Lepage, 2006, British Journal of Cancer.

Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study.

C. Lepage, J. Faivre, F. Ghiringhelli, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Management and prognosis of pancreatic cancer over a 30-year period

C. Lepage, V. Jooste, J. Faivre, 2009, British Journal of Cancer.

Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study)

C. Lepage, J. Scoazec, A. Couvelard, 2016, Neuroendocrinology.

A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma.

C. Lepage, J. Faivre, A. Bouvier, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)

A. Lièvre, C. Lepage, O. Bouché, 2020, Digestive and Liver Disease.

What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.

L. Quéro, A. Lièvre, C. Lepage, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial

L. Collette, P. Laurent-Puig, C. Lepage, 2012 .

Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.

I. Sobhani, A. Lièvre, C. Lepage, 2023, The Lancet. Oncology.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD.

C. Lepage, A. Dohan, N. Baize, 2020, Journal of geriatric oncology.

Why do guidelines supersede the conference consensus?: New French recommendations for metastatic colorectal cancer management.

C. Lepage, O. Bouché, T. Aparicio, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-ANABASE.

L. Quéro, A. Lièvre, C. Lepage, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Outcomes of anus squamous cell carcinoma. Management of anus squamous cell carcinoma and recurrences.

Anthony J. Lopez, C. Lepage, V. Jooste, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colorectal cancer screening

C. Lepage, J. Faivre, V. Dancourt, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

AGING AND THERAPEUTIC DELAY IN COLORECTAL CANCER: A FRENCH POPULATION-BASED STUDY

C. Lepage, V. Jooste, J. Faivre, 2016, Journal of Aging Research and Lifestyle.

Conditional net survival: Relevant prognostic information for colorectal cancer survivors. A French population-based study.

C. Lepage, V. Jooste, J. Faivre, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Long-term effect of faecal occult blood screening on incidence and mortality from colorectal cancer.

C. Lepage, J. Faivre, V. Dancourt, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Adjuvant treatments for gastric cancer: from practice guidelines to clinical practice.

C. Lepage, J. Faivre, P. Maingon, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer.

C. Lepage, J. Faivre, C. Lejeune, 2013, European journal of cancer.

The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers

S. Msika, T. Conroy, M. Copin, 2018, BMC Cancer.

Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms.

C. Lepage, J. Faivre, C. Lejeune, 2008, European journal of cancer.

Trends in the incidence and management of biliary tract cancer: a French population-based study.

C. Lepage, J. Faivre, A. Bouvier, 2011, Journal of hepatology.

Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study

M. Coleman, J. Fulton, B. Rachet, 2013, BMJ Open.

LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial

P. Laurent-Puig, C. Lepage, C. Borg, 2022, Annals of Oncology.

MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma

N. Magné, Olivier Saut, A. Lièvre, 2021, Cancers.

Patterns of recurrence of obstructing colon cancers after surgery for cure: a population‐based study

C. Lepage, J. Faivre, A. Bouvier, 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer

H. Blanché, C. Lepage, A. Duval, 2016, Journal of Medical Genetics.

No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial

M. Coleman, M. Parmar, M. Sydes, 2008, British Journal of Cancer.

Rising Incidence of Pancreatic Cancer in France

C. Lepage, V. Jooste, J. Faivre, 2010, Pancreas.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

A. Lièvre, P. Laurent-Puig, H. Sokol, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.

T. de Baère, E. Baudin, C. Lepage, 2019, European journal of cancer.

Chemotherapy of metastatic colon cancer in France: A population-based study.

C. Lepage, V. Jooste, A. Bouvier, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Outcomes following polypectomy for malignant colorectal polyps are similar to those following surgery in the general population

C. Lepage, V. Jooste, J. Faivre, 2017, Gut.

DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

R. Greil, R. Salazar, P. Laurent-Puig, 2016, JAMA oncology.

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

C. Lepage, G. Deplanque, V. Bourcier, 2021, Hepatology International.

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial.

F. Cianchi, C. Lepage, J. Taieb, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".

C. Lepage, J. Emile, J. Taïeb, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Trends in incidence and management of esophageal adenocarcinoma in a well-defined population.

C. Lepage, J. Faivre, A. Bouvier, 2005, Gastroenterologie clinique et biologique.

Management of gastric neuro-endocrine tumours in a large French national cohort (GTE)

E. Baudin, C. Lepage, V. Rohmer, 2017, Endocrine.

Cancer colorectal : du diagnostic au dépistage

C. Lepage, J. Faivre, J. Viguier, 2009 .

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma

C. Tournigand, C. Lepage, A. Bertaut, 2023, Journal of gastrointestinal oncology.

Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.

R. Labianca, R. Goldberg, C. Lepage, 2022, European journal of cancer.

Trends in the management of gastric cancer over a 32-year period: a French population-based study

C. Lepage, V. Jooste, J. Faivre, 2014, Gastric Cancer.

Trends in colorectal cancer incidence: a period and birth-cohort analysis in a well-defined French population

C. Lepage, V. Jooste, J. Faivre, 2011, BMC Cancer.

Biliary tract cancers have distinct epidemiological patterns and clinical characteristics according to tumour site

C. Lepage, V. Jooste, F. Ghiringhelli, 2023, HPB.

SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.

A. Lièvre, P. Laurent-Puig, C. Lepage, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

2305 Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): Results of the Phase II part

T. Baère, C. Lepage, V. Boige, 2015 .

A colonoscopy quality improvement intervention in an endoscopy unit

C. Lepage, S. Aho, O. Facy, 2022, Scientific reports.

Well-differentiated grade 3 digestive neuroendocrine tumors: Myth or reality? The PRONET study group.

C. Lepage, J. Scoazec, E. Leteurtre, 2012 .

Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.

P. Laurent-Puig, F. Puglisi, C. Lepage, 2021, Clinics and research in hepatology and gastroenterology.

Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002.

J. Bosset, R. Audisio, C. Lepage, 2012, European journal of cancer.

Net survival in recurrence-free colon cancer patients.

C. Lepage, V. Jooste, J. Faivre, 2019, Cancer epidemiology.

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

C. Lepage, R. Guimbaud, J. Raoul, 2020, British Journal of Cancer.

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

C. Lepage, J. Taieb, R. Coriat, 2018 .

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial.

C. Lepage, V. Boige, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).

C. Lepage, F. Caroli-Bosc, J. Taieb, 2020, Clinical colorectal cancer.

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

C. Lepage, R. Guimbaud, J. Raoul, 2020, British Journal of Cancer.

Adjuvant FOLFOX +/− cetuximab in full RAS and BRAF wildtype stage III colon cancer patients

P. Laurent-Puig, E. Van Cutsem, J. Tabernero, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

C. Lepage, C. Pétorin, J. Seitz, 2018 .

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma

R. Schiappa, C. Lepage, L. Faivre, 2017, Hereditary cancer in clinical practice.

Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.

J. Cercueil, C. Lepage, B. Guiu, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

P. Laurent-Puig, F. Penault-Llorca, J. Tabernero, 2017, European journal of cancer.

Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.

R. Salazar, P. Laurent-Puig, J. Tabernero, 2017 .

[Epidemiology of pancreatic cancer].

C. Lepage, A. Bouvier, S. Manfredi, 2015, Bulletin du Cancer.

DPYD Genotyping to Predict Adverse Events Following TreatmentWith Fluorouracil-Based Adjuvant Chemotherapy in PatientsWith Stage III Colon Cancer

R. Greil, R. Salazar, P. Laurent-Puig, 2016 .

Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: results of the FFCD 0904 phase II trial.

A. Lièvre, C. Lepage, X. Mirabel, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[Colorectal cancer: from diagnosis to screening].

C. Lepage, J. Faivre, J. Viguier, 2009, Gastroentérologie Clinique et Biologique.

Who is implicated in the care of digestive cancers? A population-based study over a 25-year period.

C. Lepage, J. Faivre, C. Lejeune, 2006, Gastroenterologie clinique et biologique.

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study

C. Lepage, C. Mariette, G. Piessen, 2023, Cancers.

Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.

P. Laurent-Puig, J. Tabernero, C. Lepage, 2016 .

Immunochemical faecal occult blood tests for colorectal cancer screening: no time to lose.

C. Lepage, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Is the management of hepatitis C patients appropriate? A population‐based study

C. Lepage, V. Jooste, E. Monnet, 2005, Alimentary pharmacology & therapeutics.

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial

C. Lepage, R. Guimbaud, O. Bouché, 2018, Gastric Cancer.

Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.

B. Chauffert, J. Cercueil, C. Lepage, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).

N. Magné, A. Lièvre, W. Cacheux, 2019, Journal of Clinical Oncology.

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

A. Lièvre, C. Lepage, O. Bouché, 2016 .

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial.

C. Lepage, O. Bouché, D. Pezet, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience

B. Chauffert, J. Cercueil, C. Lepage, 2013, CardioVascular and Interventional Radiology.

[Epidemiology of pancreatic cancer].

C. Lepage, A. Bouvier, S. Manfredi, 2017, Bulletin du cancer.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial.

C. Lepage, P. Rougier, M. Hebbar, 2016 .

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial

J. Pignon, M. Ducreux, C. Lepage, 2019, Expert review of pharmacoeconomics & outcomes research.

Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies?

C. Lepage, V. Jooste, J. Faivre, 2013, European journal of cancer.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.